Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
88%(7 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_4
1
11%
Ph phase_1
1
11%
Ph phase_3
7
78%

Phase Distribution

1

Early Stage

0

Mid Stage

8

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 3Large-scale testing
7(77.8%)
Phase 4Post-market surveillance
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(8)
Terminated(1)

Detailed Status

Completed8
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 37 (77.8%)
Phase 41 (11.1%)

Trials by Status

terminated111%
completed889%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_4

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

NCT03226899
completedphase_3

Lesinurad and Febuxostat Combination Extension Study in Gout

NCT01808144
completedphase_3

Lesinurad and Allopurinol Combination Extension Study in Gout

NCT01808131
completedphase_3

Combining Lesinurad With Allopurinol in Inadequate Responders

NCT01510158
completedphase_3

Combining Lesinurad With Allopurinol in Inadequate Responders

NCT01493531
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03226899Phase 4

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

Terminated
NCT01808144Phase 3

Lesinurad and Febuxostat Combination Extension Study in Gout

Completed
NCT01808131Phase 3

Lesinurad and Allopurinol Combination Extension Study in Gout

Completed
NCT01510158Phase 3

Combining Lesinurad With Allopurinol in Inadequate Responders

Completed
NCT01493531Phase 3

Combining Lesinurad With Allopurinol in Inadequate Responders

Completed
NCT01650246Phase 3

Open-Label Lesinurad Monotherapy Extension Study in Gout

Completed
NCT01510769Phase 3

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

Completed
NCT01508702Phase 3

Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

Completed
NCT01744379Phase 1

Single and Multiple Dose Study in Japanese

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9